- Home
- XENE
as 07-26-2024 4:00pm EST
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
| Founded: | 1996 | Country: | Canada |
| Employees: | N/A | City: | BURNABY |
| Market Cap: | 2.8B | IPO Year: | 2014 |
| Target Price: | $59.00 | AVG Volume (30 days): | 490.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.99 - $50.99 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 400.74% |
Stock Insider Trading Activity of Xenon Pharmaceuticals Inc. (XENE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GAROFALO ELIZABETH A. | XENE | Director | Mar 8 '24 | Sell | $45.69 | 2,092 | $95,583.48 | 0 | SEC Form 4 |
| GANNON STEVEN | XENE | Director | Mar 7 '24 | Sell | $46.45 | 1,000 | $46,450.00 | 14,000 | SEC Form 4 |
| GANNON STEVEN | XENE | Director | Mar 7 '24 | Sell | $46.25 | 5,000 | $231,250.00 | 9,000 | SEC Form 4 |
| GANNON STEVEN | XENE | Director | Mar 7 '24 | Sell | $46.30 | 5,000 | $231,512.50 | 4,000 | SEC Form 4 |
| GANNON STEVEN | XENE | Director | Mar 7 '24 | Sell | $46.20 | 2,000 | $92,402.40 | 2,000 | SEC Form 4 |
| ROBIN SHERRINGTON | XENE | EVP, Strategy & Innovation | Mar 7 '24 | Sell | $46.15 | 1,019 | $47,026.85 | 14,516 | SEC Form 4 |
| ROBIN SHERRINGTON | XENE | EVP, Strategy & Innovation | Mar 7 '24 | Sell | $46.30 | 6,118 | $283,263.40 | 8,398 | SEC Form 4 |
| PATOU GARY | XENE | Director | Dec 13 '23 | Sell | $41.05 | 7,598 | $311,897.90 | 4,902 | SEC Form 4 |
| PATOU GARY | XENE | Director | Dec 13 '23 | Sell | $38.94 | 5,100 | $198,594.00 | 23,573 | SEC Form 4 |
| PATOU GARY | XENE | Director | Dec 13 '23 | Sell | $39.10 | 2,303 | $90,047.30 | 23,573 | SEC Form 4 |
| PATOU GARY | XENE | Director | Dec 13 '23 | Sell | $39.84 | 3,977 | $158,443.68 | 23,573 | SEC Form 4 |
| PATOU GARY | XENE | Director | Dec 13 '23 | Sell | $41.05 | 7,598 | $311,897.90 | 4,902 | SEC Form 4 |
Latest Xenon Pharmaceuticals Inc. News
XENE Breaking Stock News: Dive into XENE Ticker-Specific Updates for Smart Investing
Simply Wall St.
11 days ago
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 24% Below Their Intrinsic Value Estimate
Zacks
24 days ago
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Insider Monkey
a month ago
Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50?
GlobeNewswire
2 months ago
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Simply Wall St.
2 months ago
Shareholders Will Probably Not Have Any Issues With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Compensation
GlobeNewswire
2 months ago
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
Insider Monkey
2 months ago
Hedge Funds are Racking Up Shares of This Healthcare Stock
Insider Monkey
3 months ago
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call Transcript
Compare XENE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.